STOCK TITAN

Tonix Pharmaceuticals Holding (TNXP) SEC Filings, Mar-May 2026

TNXP NASDAQ

Tonix Pharmaceuticals Holding Corp. SEC filings document a commercial-stage biotechnology company with Nasdaq-listed common stock and programs spanning CNS disorders, immunology, infectious diseases and rare diseases. Recent Form 8-K reports cover Regulation FD disclosures, selected operating and financial results, capital-structure information, commercial arrangements for TONMYA, and clinical or preclinical updates for programs such as TNX-4800, TNX-1700 and TNX-1900.

The company’s proxy and annual meeting filings describe board elections, shareholder voting results, equity incentive plan approvals, executive compensation matters and other governance subjects. Tonix filings also provide formal records of material events, exhibit-based press releases and presentations, risk-related disclosures, registered securities and public-company reporting obligations.

Rhea-AI Summary

Tonix Pharmaceuticals reported sharply higher Q1 2026 net product revenue of $6.9 million, up from $2.4 million a year earlier, driven mainly by the launch of fibromyalgia drug TONMYA and growth in migraine products Zembrace SymTouch and Tosymra.

Despite this growth, Tonix posted a larger net loss of $40.2 million versus $16.8 million in Q1 2025 as research and development spending rose to $18.2 million and selling, general and administrative costs increased to $28.6 million, reflecting commercialization and pipeline investments.

The company ended March 31, 2026 with $185.5 million in cash and cash equivalents and working capital of about $177.5 million, but disclosed that these resources, including additional equity raised in Q2 2026, are expected to fund operations only into early second quarter 2027, leading to a stated substantial doubt about its ability to continue as a going concern without new financing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
quarterly report
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. reported results of its annual shareholder meeting. Shareholders approved the 2026 Stock Incentive Plan, allowing equity-based awards to employees, directors and key consultants. They also authorized the Board, within two years of May 7, 2026, to implement one or more reverse stock splits at ratios between 1-for-2 and 1-for-250 of the then-outstanding common shares, with exact terms to be set later. Nine directors were elected and PricewaterhouseCoopers LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
current report
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. entered into an agreement with a leading group purchasing organization, effective May 1, 2026, that provides commercial insurance coverage for TONMYA to approximately 35 million U.S. lives, about 20% of roughly 177 million commercially insured individuals.

TONMYA, a first-in-class non-opioid analgesic and the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years, is also covered under Medicaid in 38 states for approximately 55 million beneficiaries, representing 73% of roughly 75 million Medicaid lives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.81%
Tags
current report
Rhea-AI Summary

Tonix Pharmaceuticals released preliminary figures for the quarter ended March 31, 2026. Net revenue from Zembrace® SymTouch® and Tosymra® was about $3.2 million, up from $2.4 million for the same quarter in 2025, reflecting higher migraine-product sales.

Net revenue from TONMYA® was about $3.7 million in the quarter, following its November 2025 launch and $1.4 million of revenue through December 31, 2025. The company believes its March 31, 2026 cash resources plus $17.4 million of second-quarter 2026 equity-offering proceeds will fund planned operations and capital needs into the second quarter of 2027.

The company emphasized these results are unaudited, preliminary estimates prepared by management and subject to change as closing procedures are completed. Its independent auditor has not reviewed this data. Tonix currently expects to file its full Quarterly Report on Form 10-Q on or about May 11, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
current report
-
Rhea-AI Summary

Tonix Pharmaceuticals reported new data and development plans for TNX-4800, a long-acting monoclonal antibody designed to prevent Lyme disease by targeting the OspA protein on Borrelia burgdorferi. The company presented Phase 1 results and program updates at the 4th Annual Ticks and Tickborne Diseases Symposium.

Phase 1, a randomized, double-blind, dose-escalation study in 44 healthy adults, found TNX-4800 to be generally safe and well tolerated, with no significant clinical or laboratory safety signals and mostly mild or moderate adverse events. Tonix plans a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study starting in the first half of 2027, pending FDA agreement, testing a fixed two-dose subcutaneous regimen given in Spring and two months later, aiming to prevent Lyme disease for six months after the initial dose.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
current report
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. filed a report describing new preclinical data on its immuno-oncology candidates TNX-1700 and TNX-4700 presented at the 2026 AACR Annual Meeting. Collaborators showed that a murine version of TNX-1700 reversed aging-associated gastric inflammation and attenuated tumor progression in aged mice.

A second study found TNX-1700 had dose-independent, linear pharmacokinetics in non-human primates and human FcRn/serum albumin transgenic mice, with all animals surviving without major weight loss. A third poster reported that TNX-4700, an anti-BTLA antibody, demonstrated potent, high-affinity binding and functional antagonism in vitro.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
current report
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. director and Chief Executive Officer Seth Lederman reported an indirect open-market purchase of 5,000 shares of common stock on March 31, 2026 through an IRA account. The weighted average purchase price was about $12.62 per share, from trades between $12.5699 and $12.625.

Following this transaction, the IRA account holds 20,001 shares indirectly, while Lederman also holds 4,005 shares directly and 1 share indirectly through Lederman & Co., an entity for which he may be deemed a control person.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
insider
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. reported Phase 1 results and next-step plans for TNX-4800, a long-acting monoclonal antibody being developed to prevent Lyme disease. The single-dose subcutaneous treatment is designed to offer about four months of protection for people in Lyme-endemic U.S. regions.

The Phase 1 trial enrolled 44 healthy adults, with 41 completing, and showed TNX-4800 was generally safe and well tolerated across doses from 0.5 to 10 mg/kg, with most side effects mild or moderate. Pharmacokinetic data showed rapid absorption, long half-life of roughly two to three months, and serum levels remaining measurable for up to 12 months.

Based on these data, Tonix plans a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study using a fixed 350 mg dose. The primary goal is to test whether TNX-4800 prevents the first occurrence of confirmed Lyme disease over the four months after dosing, with a key secondary endpoint at six months. The company expects GMP clinical material in early 2027 and aims to start Phase 2 in the first half of 2027, pending FDA clearance, with a potential controlled human infection model study in 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.30%
Tags
current report
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. is asking shareholders to approve several key items at its 2026 virtual annual meeting. Investors will vote on electing nine directors, ratifying PwC as the new independent auditor, authorizing a flexible reverse stock split, and adopting a new 2026 stock incentive plan.

The Board seeks authority to implement one or more reverse stock splits over two years, at ratios between 1:2 and 1:250, to help maintain Nasdaq listing standards tied to minimum bid price. Shareholders of record on March 19, 2026, when 13,405,401 common shares were outstanding, may vote online or by proxy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.60%
Tags
proxy
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp: The Vanguard Group filed an amendment stating it currently reports zero beneficial ownership of Tonix common stock. The filing explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries/divisions to report holdings separately and says Vanguard no longer is deemed to beneficially own securities reported by those entities. The filing lists Amount beneficially owned: 0 and Percent of class: 0%, and is signed by Ashley Grim on 03/27/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
ownership

FAQ

How many Tonix Pharmaceuticals Holding (TNXP) SEC filings are available on StockTitan?

StockTitan tracks 95 SEC filings for Tonix Pharmaceuticals Holding (TNXP), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Tonix Pharmaceuticals Holding (TNXP)?

The most recent SEC filing for Tonix Pharmaceuticals Holding (TNXP) was filed on November 13, 2026.